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Abstract 
Background/Aims     A single best endpoint for evaluating treatments of severe influenza 
requiring hospitalization has not been identified. A novel 6-category ordinal endpoint of 
patient status is being used in a randomized controlled trial (FLU-IVIG) of intravenous 
immunoglobulin (IVIG). We systematically examine four factors regarding the use of this 
ordinal endpoint that may affect power from fitting a proportional odds model: 1) 
deviations from the proportional odds assumption which result in the same overall 
treatment effect as specified in the FLU-IVIG protocol and which result in a diminished 
overall treatment effect; 2) deviations from the distribution of the placebo group  
assumed in the FLU-IVIG design; 3) the effect of patient misclassification among the 6 
categories; and 4) the number of categories of the ordinal endpoint. We also consider 
interactions between the treatment effect (i.e., Factor 1) and each other factor.  
Methods     We conducted a Monte Carlo simulation study to assess the effect of each 
factor. To study factor 1, we developed an algorithm for deriving distributions of the 
ordinal endpoint in the two treatment groups that deviated from proportional odds while 
maintaining the same overall treatment effect. For factor 2, we considered placebo group 
distributions which were more or less skewed than the one specified in the FLU-IVIG 
protocol by adding or subtracting a constant from the cumulative log odds. To assess 
factor 3, we added misclassification between adjacent pairs of categories that depend on 
subjective patient/clinician assessments. For factor 4, we collapsed some categories into 
single categories. 
Results     Deviations from proportional odds reduced power at most from 80% to 77% 
given the same overall treatment effect as specified in the FLU-IVIG protocol. 
Misclassification and collapsing categories can reduce power by over 40 and 10 
percentage points, respectively, when they affect categories with many patients and a 
discernible treatment effect. But, collapsing categories that contain no treatment effect 
can raise power by over 20 percentage points. Differences in the distribution of the 
placebo group can raise power by over 20 percentage points or reduce power by over 40 
percentage points depending on how patients are shifted to portions of the ordinal 
endpoint with a large treatment effect. 
Conclusions     Provided that the overall treatment effect is maintained, deviations from 
proportional odds marginally reduce power. However, deviations from proportional odds 
can modify the effect of misclassification, the number of categories, and the distribution 
of the placebo group on power. In general, adjacent pairs of categories with many 
patients should be kept separate to help ensure that power is maintained at the pre-
specified level. 
Keywords:     clinical trials, endpoints, proportional odds model, misspecified model, 
statistical power  
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Introduction 
Influenza causes 226,000 excess hospitalizations and more than 500,000 deaths 
worldwide.1 In spite of the large disease burden, no study has definitively demonstrated 
substantial clinical efficacy of an antiviral drug in hospitalized influenza patients.2 For 
this subpopulation, the proportion of patients dying is small, increasing the challenge to 
demonstrate treatment effects with all-cause mortality as the sole endpoint. Therefore, the 
United States Food and Drug Administration (FDA) recommends that the primary 
endpoint of randomized controlled trials evaluating new treatments include any of the 
following measures: clinical signs and symptoms, duration of hospitalization, time to 
normalization of vital signs and oxygenation, requirements for supplemental oxygen or 
assisted ventilation, and mortality. FDA guidance further states that no single best 
endpoint has been identified for studying treatments in patients hospitalized by 
influenza.2  
Primary endpoints in randomized trials of treatments for hospitalized influenza patients 
have included continuous measures of virologic activity, time to event outcomes (e.g., 
time to clinical stability) and binary outcomes (e.g., proportion of patients returning to 
premorbid status).3–7 Following the successful completion of a pilot study of intravenous 
hyperimmune immunoglobulin (IVIG),8 the International Network for Strategic 
Initiatives in Global HIV Trials (INSIGHT) initiated a trial of IVIG (FLU-IVIG) to 
evaluate its efficacy in patients hospitalized with influenza (NCTO2287467).9 To conduct 
a study with a feasible sample size and to improve the likelihood of demonstrating benefit 
relative to a binary outcome, a novel ordinal outcome of patient status serves as the 
primary endpoint of FLU-IVIG. The ordinal endpoint constructs categories of various 
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outcome assessments ranked in order of patient status (e.g., from death to resumption of 
normal activities). To our knowledge, an ordinal endpoint of clinical outcomes has not 
been used in influenza trials.  
To calculate the sample size for a trial with an ordinal endpoint, researchers must make a 
number of design decisions and assumptions. The purpose of this paper is to describe the 
ordinal endpoint used in the FLU-IVIG study and to consider the impact of four factors 
on power: 1) deviations from the proportional odds assumption which result in the same 
overall treatment effect as specified in the FLU-IVIG protocol and which result in a 
diminished overall treatment effect; 2) deviations from the distribution of the placebo 
group that researchers expect to observe in the FLU-IVIG protocol; 3) the effect of 
patient misclassification among the 6 categories; and 4) the number of categories of the 
ordinal endpoint. In addition to examining these factors separately, we also consider the 
effect of interactions between the treatment effect (i.e., factor 1) and each of the other 
factors. 
Methods 
The FLU-IVIG study was designed and is being conducted by the INSIGHT Group at 
sites in the northern and southern hemisphere. FLU-IVIG is a multicenter, double-blind, 
randomized trial comparing treatment with IVIG versus placebo in hospitalized patients 
with locally confirmed influenza A or B who have a National Early Warning Score 
(NEWS) of two or higher.10 For patients in both groups, the randomized treatment is 
administered in addition to standard of care treatment which includes anti-viral treatment. 
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The primary objective is to compare outcomes of patients in the IVIG and placebo groups 
at 7 days after randomization using an ordinal endpoint constructed with the following 6 
mutually exclusive categories: 
1)  death;  
2)  intensive care unit hospitalization (In ICU);   
3)  non-ICU hospitalization, requiring supplemental oxygen;  
4)  non-ICU hospitalization, not requiring supplemental oxygen;  
5)  discharged from the hospital, but unable to resume normal activities;  
6)  discharged from the hospital with resumption of normal activities.  
The categories were defined to delineate clear improvement and worsening in patient 
status and to yield a sufficient spread of the data for showing benefit due to IVIG. Day 7 
was chosen as the time point for comparison of ordinal endpoints because pilot data had 
established that differences between treatment groups in influenza antibody titer levels 
were greatest compared to placebo in the first few days after treatment with IVIG.8 
To estimate the sample size, we used data from a cohort study of patients hospitalized 
with influenza at many of the same sites participating in the FLU-IVIG trial to predict the 
distribution of the ordinal endpoint in the placebo group for FLU-IVIG.11–12 The 
distribution of the ordinal endpoint at day 7 for patients in the cohort study who met the 
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FLU-IVIG trial inclusion/exclusion criteria is given in Table 1. Because the cohort study 
is still in progress, we derived a more recent placebo group distribution (updated as of 
September 1st, 2015) relative to the FLU-IVIG protocol. Therefore, the category 
percentages used in our investigation differ slightly from the FLU-IVIG protocol (for the 
category percentages of the placebo group specified in the FLU-IVIG protocol, see the 
second footnote of Table 1). We refer to these category percentages as the FLU-IVIG 
design estimates. The FLU-IVIG protocol specifies that a proportional odds model will 
be used to evaluate the effect of IVIG. Under the proportional odds assumption of the 
model, the treatment effect is constant across categories between randomized groups. 
That is, the model assumes that the ratio of the odds of any better versus worse division 
of the ordinal endpoint (e.g., alive versus dead, discharged versus hospitalized or dead) 
between IVIG and placebo is constant. In FLU-IVIG, a treatment effect corresponding to 
a log odds ratio of 0.57 was deemed of interest and attainable. A log odds ratio greater 
than 0 indicates benefit due to IVIG. Under the proportional odds model, the percentage 
of subjects in each ordered category for the IVIG group is shown in Table 1 assuming a 
log odds ratio of 0.57.  
Even if the proportional odds assumption is not reasonable, the estimated log odds ratio 
from erroneously assuming a proportional odds model is still a valid measure of 
treatment efficacy. In particular, the log odds ratio can be interpreted as the average shift 
over the 6 ordered categories caused by IVIG and the score test of the log odds ratio is 
equivalent to the well-known nonparametric Wilcoxon rank-sum test.13 
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In order to detect a log odds ratio of 0.57 assuming proportional odds with 80% power at 
the 0.05 (2-sided) level of significance, a sample size of 320 patients is required.14 For 
reference, Supplemental Table 1 gives the power for detecting different log odds ratios 
with a sample size of 320 patients. Supplemental Table 2 gives the power for detecting a 
significant treatment effect under each possible way of dividing the ordinal endpoint into 
a binary endpoint. The power from each binary endpoint is substantially less than the 
power from the ordinal endpoint.  
Simulation Study Design 
We first derived different distributions of the ordinal endpoint in the placebo and IVIG 
groups under different scenarios of each factor which we describe below. For each 
scenario, we ran 10,000 simulations of the clinical trial assuming that 320 patients were 
sampled from the corresponding placebo and IVIG group distributions. For each 
simulated trial, we analyzed the data assuming a proportional odds cumulative logistic 
model and computed a Wald test statistic for the treatment effect. The empirical power is 
the proportion of the 10,000 simulations for which the Wald test statistic was significant. 
With this approach, estimates of power do not require any large sample approximations. 
The reference level of the factors in our simulation experiment corresponds to the 
assumptions used in the sample size calculation for the FLU-IVIG design; that is, the 
proportional odds assumption holds, the distribution of the placebo group is determined 
from the cohort study, no misclassification of patients among the categories of the ordinal 
endpoint occurs, and the full 6-level ordinal endpoint is used.  
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Factor 1: Treatment Effect 
We first sought to derive distributions of the IVIG group that deviated from proportional 
odds while maintaining the same overall treatment effect as specified in the FLU-IVIG 
protocol. By overall treatment effect, we mean the average (across repeated 
experimentation) estimated log odds ratio for the effect of IVIG relative to placebo from 
fitting the proportional odds model to the data. We refer to this as the average log odds 
ratio but note that this is not the arithmetic mean of the log odds ratio for every possible 
binary division of the ordinal endpoint and is a nonlinear function of the probabilities of 
each category in the ordinal endpoint in the placebo and IVIG groups.  
For large samples, the average log odds ratio of a misspecified proportional odds model 
is the value for which the expected score function equals zero. Therefore, we can 
constrain the distribution of the IVIG group such that the average log odds ratio is 
maintained across deviations from proportional odds (see the Appendix for a derivation). 
We created a novel algorithm which, given the desired average log odds ratio, the 
distribution of the ordinal endpoint in the placebo group and the proportions of 
observations in all but two categories of the treatment group, returns the proportions in 
the final two categories of the treatment group to maintain the desired average log odds 
ratio. Code to implement our algorithm in the programming language R is available as a 
GitHub repository (https://github.com/RPeterson4/Supplementary-Code-for-Evaluating-
the-Ordinal-Endpoint-for-FLU-IVIG).  
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We considered three treatment effect scenarios (T1–T3 below) that deviate from 
proportional odds while maintaining an average log odds ratio of 0.57 assuming the other 
three factors are not altered. The deviation from proportional odds is strong enough in 
each of these scenarios to yield, on average, a significant p-value for the test of the 
proportional odds assumption (at the 0.05 level) across the samples. We also considered 
two treatment effect scenarios (T4 and T5) with a log odds ratio of 0.57 across a subset of 
all possible binary divisions of the categories of the ordinal endpoint but zero elsewhere. 
In these scenarios, the overall treatment effect is diminished. The six treatment effect 
scenarios are: 
 T0: Proportional odds is satisfied and the average log odds ratio is 0.57 (FLU-IVIG 
design assumption). 
 T1: The treatment effect constantly weakens across the ordinal endpoint. The log 
odds ratio is 2.6 between the binary outcome of alive and dead patients, and then 
constantly decreases by 0.6 with each successive binary division of the ordinal 
endpoint (e.g., the log odds ratio is 2.0 for Hospitalized, not in ICU, on oxygen or 
better versus death or in ICU). 
 T2: The treatment effect is constant and positive across the most severe categories of 
the ordinal endpoint. Specifically, the log odds ratio of 1.16 for the first four binary 
divisions of the ordinal endpoint (ordering the scale from most severe outcome to 
least severe). There is no treatment effect for the last binary division (Discharged, 
back to normal activities or worse versus Discharged, not back to normal activities). 
 T3: The treatment only benefits patients in the discharged categories. That is, the log 
odds ratio is 1.16 for the last binary division and 0 for all other binary divisions.  
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 T4: The log odds ratio is 0.57 for the first four binary divisions and 0 for the last 
binary division.  
 T5: The log odds ratio is 0.57 for the last binary division and 0 for the first four 
binary divisions. 
Factor 2: Distribution of the Placebo Group 
To systematically alter the distribution of the placebo group, note that the cumulative log 
odds of being in a more versus less severe category for each possible binary split of the 
ordinal endpoint (see Supplemental Table 3) uniquely determines the placebo group 
distribution. To derive different distributions of the placebo group, we added or 
subtracted a constant from each of the cumulative log odds of being in a more versus less 
severe category from the placebo group design estimate (see the Appendix for a 
derivation). Adding (subtracting) a constant increases the proportion of patients with 
more (less) severe outcomes of the ordinal endpoint. Note that 62.9% of subjects are in 
the discharged categories of the ordinal endpoint for the placebo group design estimate. 
Therefore, having more (fewer) patients in more severe categories will yield a less (more) 
skewed distribution. The five distributions of the placebo group are: 
 P0: The placebo group distribution for the FLU-IVIG design. 
 P1: Add 0.5 to the cumulative log odds of P0 (less skewed distribution). 
 P2: Add 1 to the cumulative log odds of P0 (less skewed distribution). 
 P3: Subtract 0.5 from the cumulative log odds of P0 (more skewed distribution). 
 P4: Subtract 1 from the cumulative log odds of P0 (more skewed distribution). 
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Factor 3: Misclassification 
For our purposes, we studied misclassification among adjacent pairs of categories that 
may be difficult to distinguish between for significant numbers of patients. This 
misclassification may result from a combination of the subjective nature of the 
categories, inconsistent clinician judgment, and patients’ memory of their recovery. To 
study the effect of misclassification, we considered scenarios investigated by Whitehead 
who supposed 20% misclassification between two pairs of categories.14 Whitehead 
represented misclassification by exchanging certain percentages of patients between 
categories that could be misclassified (see the Appendix for an example). 
Here, we assumed that 20% and 40% of patients in the non-ICU hospitalized categories 
and the discharged categories could be misclassified. We chose the non-ICU hospitalized 
categories because use of oxygen during the day can be variable, and the discharged 
categories for depending on the patient’s memory of when they resumed normal 
activities. We assumed the misclassification rate to be constant across both randomized 
groups because the study is double-blind (i.e., nondifferential misclassification). We also 
considered scenarios in which 20% misclassification affected either the non-ICU 
hospitalized categories or the discharged categories but not the other. The type I error rate 
does not change under the nondifferential misclassification we assumed. The five levels 
of misclassification are: 
 M0: No misclassification (FLU-IVIG design assumption). 
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 M1: 20% misclassification between the non-ICU hospitalized categories and the 
discharged categories. 
 M2: 40% misclassification between the non-ICU hospitalized categories and the 
discharged categories. 
 M3: 20% misclassification between the non-ICU hospitalized categories. 
 M4: 20% misclassification between the discharged categories 
Factor 4: Number of Categories 
Misclassification between adjacent pairs of categories can be eliminated by collapsing 
each into a single category. Thus, we examined collapsing the non-ICU hospitalized 
categories and the discharged categories. Furthermore, the discharged categories contain 
the largest percentage of patients in each scenario on average, implying that collapsing 
them may have an outsize effect on power. Conversely, we collapsed the four most 
severe categories because they contain the smallest percentage of patients. We also 
collapsed the ordinal endpoint into a binary hospitalized or dead versus discharged 
endpoint, which is a clinically relevant cut-point. The six levels of collapsing categories 
are: 
 C0: The full 6-category ordinal endpoint (FLU-IVIG design assumption). 
 C1: Collapse the non-ICU hospitalized categories and the discharged categories. 
 C2: Collapse the non-ICU hospitalized categories. 
 C3: Collapse the discharged categories. 
 C4: Collapse the hospitalization or death categories. 
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 C5: Collapse the hospitalization or death categories and the discharged categories to 
make for a binary endpoint. 
Interactions 
As detection of the treatment effect is of primary interest for the FLU-IVIG trial, we 
explored the effect on power if the treatment effect (factor 1) and the placebo group 
distribution, misclassification, or number of categories also deviated from the levels 
assumed in the design of FLU-IVIG. This yielded three groups of two-way interactions: 
1) treatment effect scenarios and distributions of the placebo group; 2) treatment effect 
scenarios and levels of misclassification; and 3) treatment effect scenarios and number of 
categories. Due to the interacting factors, the overall treatment effect may differ from the 
0.57 log odds ratio specified in the FLU-IVIG protocol. 
Results 
Main Effects 
Provided that the average log odds ratio was maintained, treatment effect scenarios that 
violated proportional odds only marginally reduced power (see Table 1). For example, 
under treatment effect scenario T2 in which the treatment benefit is only evident over the 
most severe categories of the ordinal endpoint (hospitalization or death categories), 
power declined from 80% to 77.3%. However, both scenarios in which the log odds ratio 
was 0.57 for some binary divisions but 0 for the rest greatly reduced power, mainly due 
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to the decline in the average log odds ratio from 0.57 (0.31 and 0.25 under T4 and T5, 
respectively).  
Changes in the distribution of the placebo group from the FLU-IVIG design led to 
moderate differences in power. Less skewed placebo group distributions yielded slightly 
higher power, from 80% to 80.9% and 81.9% in scenarios P1 and P2, respectively (see 
Table 1). Conversely, distributions of the placebo group which were more skewed led to 
modest declines in power, with the most skewed distribution returning the largest loss of 
power from 80% to 73.8%. 
Table 2 shows that misclassification among the categories always reduced power by 
lowering the average log odds ratio. Scenarios in which there was greater 
misclassification, the misclassification involved more categories, or the misclassification 
was between categories containing many patients decreased power the most. For 
example, limiting the misclassification to the discharged categories, which comprise 
62.9% of patients in the distribution of the placebo group, reduced power from 80% to 
70.1%. Expanding the 20% misclassification to include the non-ICU hospitalized 
categories, which together contain 30.6% of patients, only additionally reduced power 
from 70.1% to 69.7%. 
Reducing the number of categories always lowered power (see Table 3). Generally, 
power declined more when multiple categories or categories with many patients were 
combined. For example, collapsing the discharged categories reduced power from 80% to 
65.6%, while having a binary hospitalized or dead versus discharged endpoint reduced 
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power from 80% to 63.9%. Collapsing the non-ICU hospitalized categories or the four 
most severe categories did not substantially reduce power, mainly due to the small 
percentage of patients in those categories. 
Interactions 
The power for all possible combinations of the interacting factors for the three groups of 
two-way interactions considered is given in Supplemental Tables 4-6. From these, we 
selected a subset from each group of interactions for further investigation based on their 
effect on power and clinical relevance. We present our findings in Tables 4-6.  
Many of the interactions between the treatment effect and each of the other factors were 
qualitative, that is the direction of the main effect on power changed when an additional 
factor was altered. For example, Table 4 demonstrates that the effect of deviations from 
proportional odds on power may change with different placebo group distributions. 
Power substantially increased (decreased) when treatment effect scenarios were paired 
with distributions of the placebo group that had more (fewer) patients in categories 
influenced by the treatment. For example, under treatment effect scenario T2 in which the 
treatment benefit is only evident for the hospitalization or death categories, having a less 
skewed placebo group distribution (i.e., more hospitalized or dead patients) raised power 
from 77.3% to 99.7% (see Tables 1 and 4). On the other hand, having a more skewed 
placebo group distribution reduced power from 77.3% to 16.8%. 
Similarly, Table 5 shows that misclassification may not reduce power when coupled with 
deviations from proportional odds. In some cases, it may even raise power. Under 
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treatment effect scenario T2, 20% and 40% misclassification between the non-ICU 
hospitalized categories and the discharged categories raised power from 77.3% to 86.2% 
and 92.7%, respectively (see Tables 1 and 5). This is likely because without 
misclassification the scenario assumes no treatment effect for patients discharged from 
the hospital. Misclassification, though, evens the proportions between patients who have 
and have not resumed normal activities, creating the illusion that the treatment has shifted 
patients into resuming normal activities. Consequently, the log odds ratio for Not Normal 
or worse versus Normal increased from 0 to raise the average log odds ratio and power. 
Additionally, Table 6 demonstrates that for scenarios in which the treatment effect was 
absent across a range of the ordinal endpoint, collapsing the corresponding categories 
raised power by increasing the average log odds ratio. Under treatment effect scenarios 
T1, T2, and T4 (scenarios in which the intervention primarily shows benefit for the 
hospitalization or death categories), collapsing the discharged categories increased power 
from 79.1% to 95.8%, 77.3% to 99.5%, and 33.1% to 65.6%, respectively (see Tables 1 
and 6). Conversely, collapsing categories over ranges of the ordinal endpoint with a 
discernible treatment effect reduced power. For example, under treatment effect scenarios 
T1, T2, and T4, collapsing the four most severe categories reduced power from 79.1% to 
67.0%, 77.3% to 76.0%, and 33.1% to 32.0%, respectively. 
Comparing Tables 2 and 3, collapsing the non-ICU hospitalized categories and the 
discharged categories to eliminate potential misclassification yielded greater power than 
using the 6-level ordinal endpoint when misclassification between both pairs of 
categories was 40% (65.1% versus 57.7%). When misclassification was limited to the 
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non-ICU hospitalized categories at the 20% level, collapsing those categories yielded 
approximately equal power compared to using the 6-level ordinal endpoint. Limiting 20% 
misclassification to the discharged categories generated greater power for the 6-level 
endpoint relative to collapsing those categories (70.1% versus 65.6%). 
Discussion 
To our knowledge, the FLU-IVIG study is the first randomized trial to use an ordinal 
endpoint to evaluate a novel influenza treatment. Thus, we considered it necessary to 
thoroughly examine the ordinal endpoint with respect to factors that may affect its 
statistical power for the trial. Our evaluation has found that the ordinal endpoint yields 
higher power relative to any collapse of the ordinal endpoint into a binary endpoint. 
Further, the decisions about the number of categories and assumptions made about the 
treatment effect, distribution of the placebo group, and the amount of misclassification 
can have substantial consequences for power. Provided that the overall treatment effect is 
maintained and other factors are held constant, deviations from proportional odds 
marginally reduce power. We also found that, holding other factors constant, more 
skewed placebo group distributions, misclassification of patients among the ordinal 
categories, and considering fewer ordinal categories decreased power consistent with 
previous research.14–16 
However, our analysis has shown that these general conclusions must be qualified as the 
effect of each of these factors may be reversed when another factor is varied 
simultaneously. To increase power, if the proportional odds assumption does not hold, 
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categories in which the treatment is presumed to be effective should be divided as evenly 
as possible; conversely, categories where the treatment is presumed to be less effective 
should be collapsed. For IVIG, the treatment may be more beneficial for severe cases. 
Therefore, we considered an ordinal endpoint which was granular for these patients to 
attain sufficient power. 
In contrast to previous research, 14–16 we explored deviations from proportional odds 
while holding the overall treatment effect constant. In addition, we studied the joint effect 
of multiple factors related to design decisions and assumptions about the ordinal 
endpoint. Previous research has primarily examined the effect of a single factor at a time. 
Though our results were derived with respect to FLU-IVIG, our novel algorithm and 
simulation code, which are available for download from GitHub, can be used to evaluate 
other ordinal endpoints for influenza trials. Other direct measures of patient status, such 
as those that include complications of influenza (e.g., development of pneumonia while 
on therapy) and patient-reported outcomes of influenza (e.g., the FLU-PRO instrument),17 
could be used to construct new ordinal endpoints for influenza treatments. 
More broadly, ordinal endpoints have been considered for trials studying treatments of 
vascular disease, streptococcus pneumoniae, and traumatic brain injury.18–21 In these 
trials, relative to FLU-IVIG, different parameter values (e.g., treatment effect size) may 
modify the magnitude of the effect of the four factors evaluated in this paper on power. 
Furthermore, other statistical methods like the sliding dichotomy, win ratio, and global 
rank tests may yield different power for detecting a treatment effect along an ordinal 
endpoint. 22–24 However, we anticipate that our general conclusions will hold when using 
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the proportional odds model to detect differences in the distribution of an ordinal 
endpoint across different randomized treatment groups. Moreover, our general approach 
can be used by future researchers to address concerns about the specification and 
statistical analysis of ordinal endpoints. In our study, we used the proportional odds 
model because it remains a standard tool for analyzing ordinal endpoints and will be used 
in the primary analysis for FLU-IVIG.  
Clearly, researchers must consider several factors when designing a clinical trial based on 
an ordinal endpoint including the number of categories, whether patients can be reliably 
distinguished between those categories, the anticipated treatment effect, and the 
distribution of the ordinal endpoint in the placebo group. Simulation studies allow 
researchers to explore how sensitive power is to decisions and assumptions about these 
factors. To that end, our general approach for evaluating the FLU-IVIG ordinal endpoint 
may be useful for examining other ordinal endpoints for influenza trials and other 
diseases.
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Table 1. Main effects of the treatment effect (factor 1) and placebo group distribution (factor 2) on power.  
Scenario Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
Factor 1: Treatment Effect 
T0: Proportional odds holds 
(FLU-IVIG design 
assumption) 
% Placeboa 
% IVIGb 
logORc 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
16.2 
10.5 
0.57 
14.4 
10.8 
0.57 
36.4 
36.0 
0.57 
26.5 
39.0 
 
Power (%)d 
 
Avg. logORe 
80.0 
 
0.57 
T1: Treatment effect 
constantly weakens 
% Placebo 
% IVIG 
logOR 
1.2 
0.1 
2.60 
5.3 
0.8 
2.00 
16.2 
5.8 
1.40 
14.4 
14.2 
0.80 
36.4 
48.5 
0.20 
26.5 
30.5 
 
Power (%) 
 
Avg. logOR 
79.1 
 
0.57 
T2: Treatment effect limited 
to the hospitalization or 
death categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.4 
1.16 
5.3 
1.7 
1.16 
16.2 
6.3 
1.16 
14.4 
7.2 
1.16 
36.4 
57.9 
0 
26.5 
26.5 
 
Power (%) 
 
Avg. logOR 
77.3 
 
0.57 
T3: Treatment effect limited 
to the discharged categories 
% Placebo 
% IVIG 
logOR 
1.2 
1.2 
0 
5.3 
5.3 
0 
16.2 
16.2 
0 
14.4 
14.4 
0 
36.4 
9.3 
1.16 
26.5 
53.6 
 
Power (%) 
 
Avg. logOR 
78.7 
 
0.57 
T4: Smaller treatment effect 
limited to the hospitalization 
or death categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
16.2 
10.5 
0.57 
14.4 
10.8 
0.57 
36.4 
48.5 
0 
26.5 
26.5 
Power (%) 
 
Avg. logOR 
33.1 
 
0.31 
T5: Smaller treatment effect 
limited to the discharged 
categories 
% Placebo 
% IVIG 
logOR 
1.2 
1.2 
0 
5.3 
5.3 
0 
16.2 
16.2 
0 
14.4 
14.4 
0 
36.4 
23.9 
0.57 
26.5 
39.0 
Power (%) 
 
Avg. logOR 
23.9 
 
0.25 
Factor 2: Distribution of the Placebo Group 
P1: Less skewed placebo 
group distribution 
% Placebo 
% IVIG 
logOR 
2.0 
1.1 
0.57 
8.3 
5.0 
0.57 
22.4 
15.4 
0.57 
16.6 
13.9 
0.57 
32.7 
36.6 
0.57 
18.0 
27.9 
Power (%) 
 
Avg. logOR 
80.9 
 
0.57 
P2: Even less skewed 
placebo group distribution 
% Placebo 
% IVIG 
logOR 
3.2 
1.8 
0.57 
12.7 
7.8 
0.57 
28.5 
21.5 
0.57 
17.1 
16.4 
0.57 
26.7 
33.4 
0.57 
11.7 
19.0 
Power (%) 
 
Avg. logOR 
81.9 
 
0.57 
P3: More skewed placebo 
group distribution 
% Placebo 
% IVIG 
logOR 
0.7 
0.4 
0.57 
3.3 
1.9 
0.57 
11.1 
6.8 
0.57 
11.2 
7.7 
0.57 
36.3 
31.9 
0.57 
37.3 
51.3 
Power (%) 
 
Avg. logOR 
78.6 
 
0.57 
P4: Even more skewed 
placebo group distribution 
% Placebo 
% IVIG 
logOR 
0.4 
0.3 
0.57 
2.0 
1.2 
0.57 
7.3 
4.3 
0.57 
8.1 
5.2 
0.57 
32.6 
25.6 
0.57 
49.5 
63.5 
Power (%) 
 
Avg. logOR 
73.8 
 
0.57 
Under factor 1, the treatment effect deviates from proportional odds. Under factor 2, the placebo group distribution deviates from that specified in the 
FLU-IVIG design. All scenarios assume no misclassification and that the full 6-level ordinal outcome is used. 
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The placebo group distribution specified in the FLU-IVIG design has been updated from the FLU-IVIG protocol using data from the cohort study. For 
reference, the category percentages in the FLU-IVIG protocol are 1.8, 3.6, 15.6, 14.1, 39.0, and 25.8% for Death through Discharged, back to normal 
activities categories, respectively. 
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
b% IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category. 
clogOR: (natural) logarithm of the odds ratio of the given ordinal endpoint category or more severe versus less severe between the IVIG and placebo 
groups. 
dPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
eAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Table 2. Main effect of misclassification on power (factor 3).  
Scenario Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
M1: 20% misclassification 
between the non-ICU 
hospitalized categories and 
discharged categories 
% Placeboa 
% IVIGb 
logORc 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
15.8 
10.6 
0.54 
14.8 
10.7 
0.57 
34.4 
36.6 
0.45 
28.5 
38.4 
Power (%)d 
 
Avg. logORe 
69.7 
 
0.50 
M2: 40% misclassification 
between the non-ICU 
hospitalized categories and 
discharged categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
15.5 
10.6 
0.52 
15.1 
10.7 
0.57 
32.4 
37.2 
0.33 
30.5 
37.8 
 
Power (%) 
 
Avg. logOR 
57.7 
 
0.44 
M3: 20% misclassification 
between the non-ICU 
hospitalized categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
15.8 
10.6 
0.54 
14.8 
10.7 
0.57 
36.4 
36.0 
0.57 
26.5 
39.0 
Power (%) 
 
Avg. logOR 
79.6 
 
0.57 
M4: 20% misclassification 
between the discharged 
categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
16.2 
10.5 
0.57 
14.4 
10.8 
0.57 
34.4 
36.6 
0.45 
28.5 
38.4 
Power (%) 
 
Avg. logOR 
70.1 
 
0.51 
Under factor 3, patients are misclassified between the non-ICU hospitalized categories and the discharged categories assuming the treatment effect 
(without misclassification) follows proportional odds, the distribution of the placebo group is as specified in the FLU-IVIG design, and the full 6-level 
ordinal endpoint is used.  
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
b% IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category. 
clogOR: (natural) logarithm of the odds ratio of the given ordinal endpoint category or more severe versus less severe between the IVIG and placebo 
groups. 
dPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
eAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Table 3. Main effect of the number of categories on power (factor 4). 
Scenario Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
C1: Collapse the non-ICU 
hospitalized categories and 
discharged categories 
% Placeboa 
% IVIGb 
logORc 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
30.6 
21.2 
0.57 
62.9 
75.0 
Power (%)d 
 
Avg. logORe 
65.1 
 
0.57 
C2: Collapse the non-ICU 
hospitalized categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
30.6 
21.2 
0.57 
36.4 
36.0 
0.57 
26.5 
39.0 
Power (%) 
 
Avg. logOR 
79.7 
 
0.57 
C3: Collapse the discharged 
categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
16.2 
10.5 
0.57 
14.4 
10.8 
0.57 
62.9 
75.0 
Power (%) 
 
Avg. logOR 
65.6 
 
0.57 
C4: Collapse the four most 
severe categories 
% Placebo 
% IVIG 
logOR 
37.1 
25.0 
0.57 
36.4 
36.0 
0.57 
26.5 
39.0 
Power (%) 
 
Avg. logOR 
78.8 
 
0.57 
C5: Collapse the four most 
severe categories and 
discharged categories  
(binary endpoint) 
% Placebo 
% IVIG 
logOR 
37.1 
25.0 
0.57 
62.9 
75.0 
Power (%) 
 
Avg. logOR 
63.9 
 
0.57 
Under factor 4, categories of the ordinal endpoint are collapsed assuming that the treatment effect follows proportional odds, the distribution of the 
placebo group is as specified in the FLU-IVIG design, and no misclassification. 
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
b% IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category. 
clogOR: (natural) logarithm of the odds ratio of the given ordinal endpoint category or more severe versus less severe between the IVIG and placebo 
groups. 
dPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
eAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Table 4. Effect of interacting the treatment effect (factor 1) and placebo group distribution (factor 2) on power. 
Scenario Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
T1: Treatment effect 
constantly weakens 
P2: Even less skewed 
placebo group distribution 
% Placeboa 
% IVIGb 
logORc 
3.2 
0.2 
2.60 
12.7 
2.3 
2.00 
28.5 
14.0 
1.40 
17.1 
25.4 
0.80 
26.7 
44.1 
0.20 
11.7 
13.9 
Power (%)d 
 
Avg. logORe 
99.6 
 
0.94 
T2: Treatment effect limited 
to the hospitalization or 
death categories 
P2: Even less skewed 
placebo group distribution 
% Placebo 
% IVIG 
logOR 
3.2 
1.0 
1.16 
12.7 
4.6 
1.16 
28.5 
14.4 
1.16 
17.1 
13.4 
1.16 
26.7 
54.9 
0 
11.7 
11.7 
Power (%) 
 
Avg. logOR 
99.7 
 
0.96 
T3: Treatment effect limited 
to the discharged categories  
P2: Even less skewed 
placebo group distribution 
% Placebo 
% IVIG 
logOR 
3.2 
3.2 
0 
12.7 
12.7 
0 
28.5 
28.5 
0 
17.1 
17.1 
0 
26.7 
8.6 
1.16 
11.7 
29.8 
Power (%) 
 
Avg. logOR 
19.6 
 
0.22 
T1: Treatment effect 
constantly weakens 
P4: Even more skewed 
placebo group distribution 
% Placebo 
% IVIG 
logOR 
0.4 
0.0 
2.60 
2.0 
0.3 
2.00 
7.3 
2.3 
1.40 
8.1 
6.3 
0.80 
32.6 
36.7 
0.20 
49.5 
54.4 
Power (%) 
 
Avg. logOR 
33.1 
 
0.33 
T2: Treatment effect limited 
to the hospitalization or 
death categories 
P4: Even more skewed 
placebo group distribution 
% Placebo 
% IVIG 
logOR 
0.4 
0.1 
1.16 
2.0 
0.7 
1.16 
7.3 
2.5 
1.16 
8.1 
3.1 
1.16 
32.6 
44.1 
0 
49.5 
49.5 
Power (%) 
 
Avg. logOR 
16.8 
 
0.21 
T3: Treatment effect limited 
to the discharged categories 
P4: Even more skewed 
placebo group distribution 
% Placebo 
% IVIG 
logOR 
0.4 
0.4 
0 
2.0 
2.0 
0 
7.3 
7.3 
0 
8.1 
8.1 
0 
32.6 
6.3 
1.16 
49.5 
75.9 
Power (%) 
 
Avg. logOR 
97.4 
 
0.91 
Under factors 1 and 2, the treatment effect deviates from proportional odds and the distribution of the placebo group deviates from that specified in the 
FLU-IVIG design assuming no misclassification and the full 6-level ordinal endpoint is used. The treatment effects were paired with placebo group 
distributions that had more or fewer patients in categories affected by the treatment. 
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
b% IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category. 
clogOR: (natural) logarithm of the odds ratio of the given ordinal endpoint category or more severe versus less severe between the IVIG and placebo 
groups. 
dPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
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eAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Table 5. Effect of interacting the treatment effect (factor 1) and misclassification (factor 3) on power.  
Scenario Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
T1: Treatment effect 
constantly weakens 
M1: 20% misclassification 
between the non-ICU 
hospitalized categories and 
discharged categories 
% Placeboa 
% IVIGb 
logORc 
1.2 
0.1 
2.60 
5.3 
0.8 
2.00 
16.2 
7.5 
1.14 
14.4 
12.6 
0.80 
36.4 
44.9 
0.26 
26.5 
34.1 
 
Power (%)d 
 
Avg. logORe 
79.1 
 
0.57 
T1: Treatment effect 
constantly weakens 
M2: 40% misclassification 
between the non-ICU 
hospitalized categories and 
discharged categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.1 
2.60 
5.3 
0.8 
2.00 
15.5 
9.2 
0.92 
15.1 
10.9 
0.80 
32.4 
41.3 
0.32 
30.5 
37.7 
Power (%) 
 
Avg. logOR 
79.6 
 
0.57 
T2: Treatment effect limited 
to the hospitalization or 
death categories 
M1: 20% misclassification 
between the non-ICU 
hospitalized categories and 
discharged categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.4 
1.16 
5.3 
1.7 
1.16 
16.2 
6.5 
1.12 
14.4 
7.0 
1.16 
36.4 
51.7 
0.20 
26.5 
32.8 
 
Power (%) 
 
Avg. logOR 
86.2 
 
0.64 
T2: Treatment effect limited 
to the hospitalization or 
death categories 
M2: 40% misclassification 
between the non-ICU 
hospitalized categories and 
discharged categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.4 
1.16 
5.3 
1.7 
1.16 
15.5 
6.6 
1.08 
15.1 
6.8 
1.16 
32.4 
45.4 
0.38 
30.5 
39.1 
Power (%) 
 
Avg. logOR 
92.7 
 
0.71 
T3: Treatment effect limited 
to the discharged categories 
M1: 20% misclassification 
between the non-ICU 
hospitalized categories and 
discharged categories 
% Placebo 
% IVIG 
logOR 
1.2 
1.2 
0 
5.3 
5.3 
0 
15.8 
15.8 
0 
14.8 
14.8 
0 
36.4 
18.2 
0.71 
26.5 
44.7 
Power (%) 
 
Avg. logOR 
38.0 
 
0.33 
T3: Treatment effect limited 
to the discharged categories 
M2: 40% misclassification 
% Placebo 
% IVIG 
logOR 
1.2 
1.2 
0 
5.3 
5.3 
0 
15.5 
15.5 
0 
15.1 
15.1 
0 
32.4 
27.0 
0.24 
30.5 
35.9 
Power (%) 
 
Avg. logOR 
7.5 
 
0.24 
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between the non-ICU 
hospitalized categories and 
discharged categories 
Under factors 1 and 3, the treatment effect deviates from proportional odds and patients are misclassified between the non-ICU hospitalized categories 
and the discharged categories. We assume the distribution of the placebo group is as specified in the FLU-IVIG design and the full 6-level ordinal 
endpoint is used. 
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
b% IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category. 
clogOR: (natural) logarithm of the odds ratio of the given ordinal endpoint category or more severe versus less severe between the IVIG and placebo 
groups. 
dPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
eAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Table 6. Effect of interacting the treatment effect (factor 1) and number of categories (factor 4) on power.  
Scenario Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
T1: Treatment effect 
constantly weakens 
C3: Collapse the discharged 
categories 
% Placeboa 
% IVIGb 
logORc 
1.2 
0.1 
2.60 
5.3 
0.8 
2.00 
16.2 
5.8 
1.40 
14.4 
14.2 
0.80 
62.9 
79.0 
Power (%)d 
 
Avg. logORe 
95.8 
 
0.89 
T1: Treatment effect 
constantly weakens 
C4: Collapse the four most 
severe categories 
% Placebo 
% IVIG 
logOR 
37.1 
21.0 
0.80 
36.4 
48.5 
0.20 
26.5 
30.5 
 
Power (%) 
 
Avg. logOR 
67.0 
 
0.50 
T2: Treatment effect limited 
to the hospitalization or 
death categories 
C3: Collapse the discharged 
categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.4 
1.16 
5.3 
1.7 
1.16 
16.2 
6.3 
1.16 
14.4 
7.2 
1.16 
62.9 
84.4 
Power (%) 
 
Avg. logOR 
99.5 
 
1.16 
T2: Treatment effect limited 
to the hospitalization or 
death categories 
C4: Collapse the four most 
severe categories 
% Placebo 
% IVIG 
logOR 
37.1 
15.6 
1.16 
36.4 
57.9 
0 
26.5 
26.5 
Power (%) 
 
Avg. logOR 
76.0 
 
0.56 
T3: Treatment effect limited 
to the discharged categories 
C4: Collapse the four most 
severe categories 
% Placebo 
% IVIG 
logOR 
37.1 
37.1 
0 
36.4 
9.3 
1.16 
26.5 
53.6 
Power (%) 
 
Avg. logOR 
80.5 
 
0.60 
T4: Smaller treatment effect 
limited to the hospitalization 
or death categories 
C3: Collapse the discharged 
categories 
% Placebo 
% IVIG 
logOR 
1.2 
0.7 
0.57 
5.3 
3.1 
0.57 
16.2 
10.5 
0.57 
14.4 
10.8 
0.57 
62.9 
75.0 
Power (%) 
 
Avg. logOR 
65.6 
 
0.57 
T4: Smaller treatment effect 
limited to the hospitalization 
or death categories 
C4: Collapse the four most 
severe categories 
% Placebo 
% IVIG 
logOR 
37.1 
25.0 
0.57 
36.4 
48.5 
0 
26.5 
26.5 
Power (%) 
 
Avg. logOR 
32.0 
 
0.31 
T5: Smaller treatment effect 
limited to the discharged 
categories 
% Placebo 
% IVIG 
logOR 
37.1 
37.1 
0 
36.4 
23.9 
0.57 
26.5 
39.0 
Power (%) 
 
Avg. logOR 
25.7 
 
0.27 
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C4: Collapse the four most 
severe categories 
Under factors 1 and 4, the treatment effect deviates from proportional odds and categories of the ordinal endpoint are collapsed assuming the 
distribution of the placebo group is as specified in the FLU-IVIG design and no misclassification. Categories were collapsed according to whether or not 
they contained the treatment effect. 
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
b% IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category. 
clogOR: (natural) logarithm of the odds ratio of the given ordinal endpoint category or more severe versus less severe between the IVIG and placebo 
groups. 
dPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
eAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Appendix 
Supplemental Table 1. Power to detect a significant treatment effect. 
logORa 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 
Power (%)b 2.5 7.2 16.6 31.8 50.8 69.7 84.4 93.4 97.7 99.4 99.9 
Power is computed at the 0.05 (2-sided) level with a sample size of 320 as a function of the log odds ratio assuming the treatment effect follows 
proportion odds, the distribution of the placebo group is as specified in the FLU-IVIG design, no misclassification, and the full 6-level ordinal endpoint 
is used. 
alogOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model 
assuming that proportional odds holds. 
bPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
 
Supplemental Table 2. Power for detecting a significant treatment effect for all possible ways of dividing the ordinal endpoint into a binary endpoint. 
Category Death 
versus In 
ICU or 
better 
In ICU or worse 
versus 
Hospitalized, not 
in ICU, on oxygen 
Hospitalized, not in ICU, on 
oxygen or worse versus 
Hospitalized, not in ICU, 
not on oxygen or better 
Hospitalized, not in ICU, 
not on oxygen or worse 
versus Discharged, not back 
to normal activities or better 
Discharged, not back to 
normal activities or worse 
versus Discharged, back 
to normal activities 
Power (%)a 0.59 12.8 48.9 63.9 66.2 
Power is computed at the 0.05 (2-sided) level with a log odds ratio of 0.57 and sample size of 320 assuming the treatment effect follows proportion 
odds, the distribution of the placebo group is as specified in the FLU-IVIG design, no misclassification, and the full 6-level ordinal endpoint is used. 
aPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level.
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Supplemental Table 3. Altering the distribution of the placebo group.  
Placebo Group Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
P0: The placebo group 
from the FLU-IVIG design 
% Placeboa 
Cumulative 
log oddsb 
1.2 
-4.41 
5.3 
-2.67 
16.2 
-1.23 
14.4 
-0.53 
36.4 
1.02 
26.5 
P1: Less skewed placebo 
group distribution 
% Placebo 
Cumulative 
log odds 
2.0 
-3.91 
8.3 
-2.17 
22.4 
-0.73 
16.6 
-0.03 
32.7 
1.52 
18.0 
P2: Even less skewed 
placebo group distribution 
% Placebo 
Cumulative 
log odds 
3.2 
-3.41 
12.7 
-1.67 
28.5 
-0.23 
17.1 
0.47 
26.7 
2.02 
11.7 
P3: More skewed placebo 
group distribution 
% Placebo 
Cumulative 
log odds 
0.7 
-4.91 
3.3 
-3.17 
11.1 
-1.73 
11.2 
-1.03 
36.3 
0.52 
37.3 
P4: Even more skewed 
placebo group distribution 
% Placebo 
Cumulative 
log odds 
0.4 
-5.41 
2.0 
-3.67 
7.3 
-2.23 
8.1 
-1.53 
32.6 
0.02 
49.5 
 
Altering the distribution of the placebo group specified in the FLU-IVIG design to be more or less skewed by changing its cumulative log odds. The 
derivation of the cumulative log odds to the probabilities in each category is given in the section below. 
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
bCumulative log odds: (natural) logarithm of the odds of the given category or more severe versus less severe.  
Derivation of the cumulative log odds for the distribution of the placebo group 
For an ordinal endpoint 𝑌, the cumulative log odds 𝐶𝑗 for level 𝑗 out of 𝐽 total levels in the distribution of the placebo group is: 
log (
𝑃(𝑌 ≤ 𝑗)
𝑃(𝑌 > 𝑗)
) = 𝐶𝑗  𝑓𝑜𝑟 𝑗 = 1,2, … 𝐽 − 1 
To return to the cumulative probability, that is, 𝑃(𝑌 ≤ 𝑗), use the expit function on 𝐶𝑗: 
𝑒𝐶𝑗
1 +  𝑒𝐶𝑗
∗ 100 = 𝑃(𝑌 ≤ 𝑗) 
The probability that 𝑌 assumes level 𝑗, that is 𝑃(𝑌 = 𝑗), is then derived as: 
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𝑃(𝑌 = 𝑗) = 𝑃(𝑌 ≤ 𝑗) − 𝑃(𝑌 ≤ 𝑗 − 1) 
A demonstration using patients in Death or ICU for P0: 
log (
1.2 + 5.3
100 − (1.2 + 5.3)
) = − 2.67 
𝑒−2.67
1 +  𝑒−2.67
∗ 100 =  6.5 = 1.2 + 5.3 
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Supplemental Table 4. Effect of all possible interactions of the treatment effects and placebo group distributions on power. 
T1: Treatment 
effect constantly 
weakens 
T2: Treatment effect 
limited to the 
hospitalization or 
death categories 
T3: Treatment 
effect limited to the 
discharged 
categories 
T4: Smaller treatment 
effect limited to the 
hospitalization or 
death categories 
T5: Smaller treatment 
effect limited to the 
discharged categories 
P1: Less skewed placebo 
group distribution 
Power (%)a 
Avg. logORb 
95.8 
0.76 
96.7 
79.2 
47.2 
0.38 
52.8 
0.42 
12.4 
0.16 
P2: Even less skewed 
placebo group distribution 
Power (%) 
Avg. logOR 
99.6 
0.94 
99.7 
0.96 
19.6 
0.22 
67.6 
0.48 
6.5 
0.09 
P3: More skewed placebo 
group distribution 
Power (%) 
Avg. logOR 
54.5 
0.43 
40.8 
0.37 
93.9 
0.77 
16.8 
0.21 
39.9 
0.35 
P4: Even more skewed 
placebo group distribution 
Power (%) 
Avg. logOR 
33.1 
0.33 
16.8 
0.21 
97.4 
0.91 
8.4 
0.13 
51.2 
0.44 
Bolded interactions were chosen for mention in the text of the paper. 
aPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
bAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Supplemental Table 5. Effect of all possible interactions of the treatment effects and misclassification on power. 
T1: Treatment 
effect constantly 
weakens 
T2: Treatment effect 
limited to the 
hospitalization or 
death categories 
T3: Treatment 
effect limited to the 
discharged 
categories 
T4: Smaller treatment 
effect limited to the 
hospitalization or 
death categories 
T5: Smaller treatment 
effect limited to the 
discharged categories 
M1: 20% 
misclassification between 
the non-ICU hospitalized 
categories and discharged 
categories 
Power (%)a 
Avg. logORb 
79.1 
0.57 
86.2 
0.64 
38.0 
0.33 
40.4 
0.35 
11.3 
0.15 
M2: 40% 
misclassification between 
the non-ICU hospitalized 
categories and discharged 
categories 
Power (%) 
Avg. logOR 
79.6 
0.57 
92.7 
0.71 
7.5 
0.24 
48.0 
0.39 
4.4 
0.49 
M3: 20% 
misclassification between 
the non-ICU hospitalized 
categories 
Power (%) 
Avg. logOR 
76.2 
0.56 
76.9 
0.57 
79.1 
0.58 
33.1 
0.31 
23.6 
0.25 
M4: 20% 
misclassification between 
the discharged categories 
Power (%) 
Avg. logOR 
82.4 
0.60 
86.8 
0.64 
38.0 
0.34 
40.9 
0.36 
11.2 
0.15 
Bolded interactions were chosen for mention in the text of the paper. 
aPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
bAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Supplemental Table 6. Effect of all possible interactions of the treatment effects and number of categories on power. 
T1: Treatment 
effect constantly 
weakens 
T2: Treatment effect 
limited to the 
hospitalization or 
death categories 
T3: Treatment 
effect limited to the 
discharged 
categories 
T4: Smaller treatment 
effect limited to the 
hospitalization or 
death categories 
T5: Smaller treatment 
effect limited to the 
discharged categories 
C1: Collapse the non-ICU 
hospitalized categories 
and discharged categories 
Power (%)a 
Avg. logORb 
92.3 
0.85 
99.4 
1.18 
0.05 
0 
65.4 
0.57 
0.05 
0 
C2: Collapse the non-ICU 
hospitalized categories 
Power (%) 
Avg. logOR 
72.4 
0.53 
76.4 
0.57 
80.0 
0.59 
32.4 
0.31 
24.2 
0.26 
C3: Collapse the 
discharged categories 
Power (%) 
Avg. logOR 
95.8 
0.89 
99.5 
1.16 
0.05 
0 
65.6 
0.57 
0.05 
0 
C4: Collapse the four 
most severe categories 
Power (%) 
Avg. logOR 
67.0 
0.50 
76.0 
0.56 
80.5 
0.60 
32.0 
0.31 
25.7 
0.27 
C5: Collapse the four 
most severe categories 
and discharged categories 
(binary endpoint) 
Power (%) 
Avg. logOR 
88.9 
0.81 
99.4 
1.18 
0.05 
0 
64.5 
0.57 
0.05 
0 
Bolded interactions were chosen for mention in the text of the paper. 
aPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the treatment effect was significant at the two-sided 0.05 
level. 
bAvg. logOR: average of the estimated log odds ratio across the 10,000 simulated datasets from fitting a proportional odds cumulative logistic model. 
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Deviations from proportional odds while maintaining the same overall treatment effect 
For the ith patient, assume that we have a 3-level ordinal endpoint 𝑌𝑖 and define: 
 𝑝1, 𝑝2, 𝑝3 are the true probabilities in the first, second, and third levels of the 
ordinal endpoint for the placebo group, respectively. 
 𝑞1, 𝑞2, 𝑞3 are the corresponding true probabilities in the treatment group. 
 𝐴𝑖 is an indicator variable for whether or not the ith patient is randomized to the 
treatment group. 
 𝑍𝑖 , 𝑉𝑖 are indicator variables for whether or not 𝑌𝑖 = 1 and 𝑌𝑖 = 2, respectively, 
for the ith patient. 
 
Note that 𝑝3 = 1 − 𝑝1 − 𝑝2 and 𝑞3 = 1 − 𝑞1 − 𝑞2; therefore, the distribution of the ordinal 
endpoint in the placebo and treatment groups is uniquely determined by the four parameters 𝑝1,
𝑝2, 𝑞1, and 𝑞2. If we assume a proportional odds model, we can express 𝑝1, 𝑝2, 𝑞1,  and 𝑞2 in 
terms of three model parameters. Let 𝛼1 and 𝛼2 represent the log odds of being in level 1 and in 
level 1 or level 2, respectively, for subjects randomized to the placebo group and let 𝛽 represent 
the log odds ratio of the treatment group to the control group. Assuming proportional odds, 𝛼1 =
log (
𝑝1
1− 𝑝1
), 𝛼2 = log (
𝑝1+𝑝2
1− 𝑝1−𝑝2
), and 𝛽 = log (
𝑞1∗(1−𝑝1)
𝑝1∗(1− 𝑞1)
) = log (
(𝑞1+𝑞2)∗(1−𝑝1−𝑝2)
(𝑝1+𝑝2)∗(1− 𝑞1−𝑞2)
). 
Under this model, the log likelihood for 𝛼1, 𝛼2, 𝛽 is given by:  
log(𝐿(𝛼1, 𝛼2, 𝛽))  
= ∑{(1 −  𝐴𝑖)[
𝑛
𝑖=1
𝑍𝑖log (
𝑒𝛼1
𝑒𝛼1 + 1
) +  𝑉𝑖log (
𝑒𝛼2 − 𝑒𝛼1
(𝑒𝛼1 + 1)(𝑒𝛼2 + 1)
) 
+(1 −  𝑍𝑖 − 𝑉𝑖)log (
𝑒𝛼1 + 1
(𝑒𝛼1 + 1)(𝑒𝛼2 + 1)
)]} 
 + ∑{𝐴𝑖[
𝑛
𝑖=1
𝑍𝑖log (
𝑒𝛼1+𝛽
𝑒𝛼1+𝛽 + 1
) +  𝑉𝑖log (
𝑒𝛼2 − 𝑒𝛼1
(𝑒𝛼1+𝛽 + 1)(𝑒𝛼2 + 𝑒−𝛽)
) 
+ (1 −  𝑍𝑖 − 𝑉𝑖)log (
𝑒𝛼1 + 𝑒−𝛽
(𝑒𝛼1+𝛽 + 1)(𝑒𝛼2 + 𝑒−𝛽)
)]} 
Regardless of whether or not the proportional odds model is correctly specified, we can obtain 
maximum likelihood estimates for 𝛼1,  𝛼2, and 𝛽 (i.e., 𝛼1̂, 𝛼2̂, ?̂?, the values of 𝛼1,  𝛼2,  and 𝛽 
which maximize the log likelihood above).  If the proportional odds assumption is not correct, ?̂? 
is still an estimate of the treatment effect across all levels of the ordinal endpoint but cannot be 
interpreted as the constant log odds ratio of the treatment group to the placebo group across all 
binary divisions of the ordinal scale.  
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As noted in the main text, we sought to derive distributions of the treatment group that deviated 
from proportional odds while maintaining the same overall treatment effect specified in the 
design of FLU-IVIG. By overall treatment effect, we mean the average (across repeated 
experimentation) estimated log odds ratio for the effect of the intervention relative to placebo 
from fitting a proportional odds cumulative logistic regression model to the data (i.e., 𝐸(?̂?)).  
Let 𝛼10 = 𝐸(𝛼1̂),  𝛼20 = 𝐸(𝛼2̂), and 𝛽0 = 𝐸(?̂?) represent the average estimated cumulative log 
odds and log odds ratio. Asymptotically, 𝛼10, 𝛼20,  and 𝛽0 are the values of  𝛼1,  𝛼2, and 𝛽 for 
which the expected score is equal to zero.25 That is for a fixed sample size, 𝛼10, 𝛼20,  and 𝛽0 are 
(approximately) the values which solve the following system of equations (1) 
𝐸 [
𝑑
𝑑𝛼1
log(𝐿(𝛼1, 𝛼2, 𝛽))]] = 0; (2) 𝐸[
𝑑
𝑑𝛼2
log(𝐿(𝛼1, 𝛼2, 𝛽))] = 0; and (3) 
𝐸[
𝑑
𝑑𝛽
log(𝐿(𝛼1, 𝛼2, 𝛽))] = 0. Note that: 
𝐸[
𝑑
𝑑𝛽
log(𝐿(𝛼1, 𝛼2, 𝛽))] 
= 𝐸{𝐴𝑖[𝑍𝑖
𝑒𝛼1+𝛼2+2𝛽 + 2𝑒𝛼2+𝛽 + 1
(𝑒𝛼1+𝛽 + 1)(𝑒𝛼2+𝛽 + 1)
+ 𝑉𝑖
1
𝑒𝛼1+𝛽 + 1
−
𝑒𝛼2+𝛽
𝑒𝛼2+𝛽 + 1
]} 
= 𝐸[𝐸{𝐴𝑖[𝑍𝑖
𝑒𝛼1+𝛼2+2𝛽 + 2𝑒𝛼2+𝛽 + 1
(𝑒𝛼1+𝛽 + 1)(𝑒𝛼2+𝛽 + 1)
+ 𝑉𝑖
1
𝑒𝛼1+𝛽 + 1
−
𝑒𝛼2+𝛽
𝑒𝛼2+𝛽 + 1
]}|𝐴𝑖] 
= 𝐸{𝐴𝑖[𝐸(𝑍𝑖|𝐴𝑖)
𝑒𝛼1+𝛼2+2𝛽 + 2𝑒𝛼2+𝛽 + 1
(𝑒𝛼1+𝛽 + 1)(𝑒𝛼2+𝛽 + 1)
+ 𝐸(𝑉𝑖|𝐴𝑖)
1
𝑒𝛼1+𝛽 + 1
−
𝑒𝛼2+𝛽
𝑒𝛼2+𝛽 + 1
]} 
Note that 𝐸(𝑍𝑖|𝐴𝑖) = 𝐴𝑖𝑞1 + (1 − 𝐴𝑖)𝑝1 and 𝐸(𝑉𝑖|𝐴𝑖) =  𝐴𝑖𝑞2 + (1 − 𝐴𝑖)𝑝2. We then have:  
𝐸[
𝑑
𝑑𝛽
log(𝐿(𝛼1, 𝛼2, 𝛽))] 
=  𝐸{𝐴𝑖𝑞1
𝑒𝛼1+𝛼2+2𝛽 + 2𝑒𝛼2+𝛽 + 1
(𝑒𝛼1+𝛽 + 1)(𝑒𝛼2+𝛽 + 1)
+ 𝐴𝑖𝑞2
1
𝑒𝛼1+𝛽 + 1
− 𝐴𝑖
𝑒𝛼2+𝛽
𝑒𝛼2+𝛽 + 1
} 
Because 𝐴𝑖 is the only random variable in the above equation with 𝐸(𝐴𝑖) = 0.5 (due to the 1:1 
allocation ratio between the randomized groups), we have: 
= 𝑞1
𝑒𝛼1+𝛼2+2𝛽 + 2𝑒𝛼2+𝛽 + 1
(𝑒𝛼1+𝛽 + 1)(𝑒𝛼2+𝛽 + 1)
+ 𝑞2
1
𝑒𝛼1+𝛽 + 1
−
𝑒𝛼2+𝛽
𝑒𝛼2+𝛽 + 1
= 0 
A similar analysis can be used to simplify 𝐸[
𝑑
𝑑𝛼1
log(𝐿(𝛼1, 𝛼2, 𝛽))]] and 
 𝐸[
𝑑
𝑑𝛼2
log(𝐿(𝛼1, 𝛼2, 𝛽))] which will be functions of 𝛼1, 𝛼2, 𝛽, and the true probabilities in each 
level of the treatment (𝑞1 and 𝑞2) and control group (𝑝1 and 𝑝2). 
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To derive distributions of the treatment group that deviated from proportional odds while 
maintaining the same overall treatment effect, we can fix 𝛽 (the overall treatment effect), 𝑝1 and 
𝑝2 (the probabilities in the first two categories of the control group), and 𝑞1 (the probability in 
the first category of the treatment group) to solve the system of three (nonlinear) equations for 
𝑞2, 𝛼1 and 𝛼2. This approach generalizes to ordinal endpoints with any number of outcome 
levels. 
Code to implement this algorithm in the programming language R is available as a GitHub 
repository (https://github.com/RPeterson4/Supplementary-Code-for-Evaluating-the-Ordinal-
Endpoint-for-FLU-IVIG). 
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Misclassification among the categories of the ordinal endpoint 
Scenario Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
M0: No Misclassification % Placeboa 
% IVIGb 
1.2 
0.7 
5.3 
3.1 
16.2 
10.5 
14.4 
10.8 
36.4 
36.0 
 
26.5 
39.0 
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
b% IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category. 
 
Misclassification is added between the oxygen and discharged categories by exchanging fixed percentages of patients between 
the respective categories for each pair for both randomized groups. An example for M1, which adds 20% misclassification 
between the non-ICU hospitalized categories and the discharged categories. 
 
M1 Placebo Hospitalized, not in ICU, on oxygen = 16.2 * 0.8 + 14.4 * 0.2 = 15.8 
M1 Placebo Hospitalized, not in ICU, not on oxygen = 16.2 * 0.2 + 14.4 * 0.8 = 14.8 
M1 Placebo Discharged, not back to normal activities = 36.4 * 0.8 + 26.5 * 0.2 = 34.4 
M1 Placebo Discharged, back to normal activities = 36.4 * 0.2 + 26.5 * 0.8 = 28.5 
 
M1 IVIG Hospitalized, not in ICU, on oxygen = 10.5 * 0.8 + 10.8 * 0.2 = 10.6 
M1 IVIG Hospitalized, not in ICU, not on oxygen = 10.5 * 0.2 + 10.8 * 0.8 = 10.7 
M1 IVIG Discharged, not back to normal activities = 36.0 * 0.8 + 39.0 * 0.2 = 36.6 
M1 IVIG Discharged, back to normal activities = 36.0 * 0.2 + 39.0 * 0.8 = 38.4 
 
This yields the placebo and IVIG group distributions for M1: 
 
Scenario Death In 
ICU 
Hospitalized, 
not in ICU, 
on oxygen 
Hospitalized, 
not in ICU, not 
on oxygen 
Discharged, not 
back to normal 
activities 
Discharged, 
back to normal 
activities 
M1: 20% misclassification 
between the non-ICU 
hospitalized categories and 
discharged categories 
% Placeboa 
% IVIGb 
1.2 
0.7 
5.3 
3.1 
15.8 
10.6 
14.8 
10.7 
34.4 
36.6 
 
28.5 
38.4 
a% Placebo: percentage of patients in the placebo group for the given ordinal endpoint category. 
b% IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category. 
